Clinical trial
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or…
NCT00098579 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00098579 |
|---|---|
| Title | Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery |
| Official title | Phase I Trial of Doxorubicin and Alvocidib (Flavopiridol; NCI Supplied Agent, NSC 649890) in the Treatment of Metastatic Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | alvocidib, doxorubicin hydrochloride |
| Enrollment | 36 |
| Start date | Oct 1, 2004 |
| Primary completion | Jul 1, 2011 |
| First posted | Dec 8, 2004 |
| Last update posted | Mar 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: